Etoposide / Extensive Stage Small Cell Lung Cancer / Small Cell Lung Cancer · Phase 3 Trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

ClinicalTrials.gov · September 8, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 3 trial registration comparing tarlatamab plus durvalumab, carboplatin, and etoposide against durvalumab, carboplatin, and etoposide in first-line extensive-stage small-cell lung cancer. No results are posted in this registry record, so efficacy and safety outcomes remain unknown.

What was studied

Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer; age from 18 Years; to 99 Years. Intervention: Tarlatamab + Durvalumab + Carboplatin + Etoposide. Compared with: Durvalumab + Carboplatin + Etoposide — Active Comparator. n = 350. 164 sites across 26 countries.

Key findings

Safety

This is a registry record only; no efficacy, safety, or outcome data are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Overall Survival (OS) (assessed at Up to approximately 3.5 years); Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed) (assessed at Up to approximately 3.5 years)

DesignPhase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose

PopulationSmall-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer; age from 18 Years; to 99 Years

Sample size350

InterventionTarlatamab + Durvalumab + Carboplatin + Etoposide

ComparatorDurvalumab + Carboplatin + Etoposide — Active Comparator

Setting164 sites across 26 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment350

PhasePhase 3

Primary endpoint 1Overall Survival (OS), up to approximately 3.5 years

Primary endpoint 2Progression-free survival (PFS, BICR-assessed), up to approximately 3.5 years

Caveats

This is a registry record only; no efficacy, safety, or outcome data are reported.
No effect sizes, p-values, confidence intervals, or comparative results are available.
Study is active but not recruiting, so results may be forthcoming but are not yet posted.
Randomization method, blinding strategy, and stratification factors are not detailed in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Phase 3 randomized controlled trial comparing two active drug combinations.

Directness

strong

Hard clinical endpoints: overall survival and progression-free survival in ES-SCLC.

Consistency

insufficient

No results reported in this registry record; consistency cannot be assessed.

Risk of bias

insufficient

Blinded independent central review planned for PFS; other bias mitigation not detailed here.

Sample adequacy

moderate

Planned enrollment 350 participants; adequacy depends on unreported effect size assumption.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07005128). This is a study registration, not published results. Lead sponsor: Amgen. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 350 participants (ACTUAL). Conditions: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer. Interventions: DRUG: Tarlatamab; DRUG: Durvalumab; DRUG: Carboplatin; DRUG: Etoposide. Primary outcome measures: Overall Survival (OS) , Up to approximately 3.5 years; Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed) , Up to approximately 3.5 years. Brief summary: The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

EtoposideExtensive Stage Small Cell Lung CancerAmgenSmall Cell Lung CancerNCT07005128CarboplatinDurvalumabTarlatamab